In this conference poster, Diaceutics explore the implementation of the In Vitro Diagnostic Device Regulation (IVDR) (EU 2017/746), which comes into full effect in May 2022, could potentially disrupt current PD-L1 testing practice for all indications as companion diagnostics will, for the first time in the EU, be regulated.
Non-Small Cell Lung Cancer (NSCLC) PD-L1 Testing Landscape Challenges in the Context of Upcoming In Vitro Diagnostics Regulation (IVDR) Implementation
This poster address the Non-Small Cell Lung Cancer PD-L1 testing landscape. To view the poster, sign in to DXRX.
Authors: Gwendolyn Courtois MSc2, Lauren Parnham2, Katherine E. Keating PhD2, Peter Riccelli PhD1, Dave Smart PhD2, Susanne Munksted MSc2, Jordan Clark MPhil2, Keith Kerr MD, FRCPath3